SPC 15
Alternative Names: SPC-15Latest Information Update: 13 Nov 2025
At a glance
- Originator Columbia University
- Developer Silo Pharma
- Class Antidepressants; Anxiolytics
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anxiety disorders; Post-traumatic stress disorders
Most Recent Events
- 23 Oct 2025 Silo expected to conduct meeting with US FDA to confirm the final data points needed to open an IND before year-end in Post-traumatic stress disorders in November 2025
- 23 Oct 2025 Silo Pharma plans to submit IND to US FDA for Post-traumatic stress disorder and Anxiety disorders in 2026 (Intranasal).
- 09 Sep 2025 Columbia University has patent protection for prophylactic efficacy of serotonin 4 receptor agonists against stress in Japan